Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

American Heart Journal

Volumn 163, Issue 3, 2012, Pages 508-514

  Tonkin, Andrew ^a   Hunt, David ^b   Voysey, Merryn ^c   Kesäniemi, Antero ^d   Hamer, Andrew ^e   Waites, Jonathon ^f   Mahar, Leo ^g   Mann, Stewart ^h   Glasziou, Paul ⁱ   Forder, Peta ^c   Simes, John ^c   Keech, Anthony C ^c  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF OULU   (Finland)

^e NELSON HOSPITAL   (New Zealand)

^f Coffs Harbour Cardiovascular Clinic ^*  (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

ⁱ BOND UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84858309358     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.12.004     Document Type: Article

References (29)

1. P. Pajunen, H. Koukkunen, and M. Ketonen Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study Diabetologia 48 2005 2519 2554
2. J.R. Burnett, and M.W. Huff Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia Exp Opin Invest Drugs 15 2006 1337 1351
3. P.W.F. Wilson, R.B. D'Agostino, and D. Levy Prediction of coronary heart disease risk factor categories Circulation 97 1998 1837 1847
4. M.R. Taskinen Diabetic dyslipidaemia: from basic research to clinical practice Diabetologia 46 2003 733 749
5. A. Fontbonne, E. Eschwege, and F. Cambien Hypertriglyceridemia as a risk factor of coronary heart-disease mortality in subjects with impaired glucose-tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study Diabetologia 32 1989 300 304
6. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
7. R. Scott, R. O'Brien, and G. Fulcher Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
8. UK Prospective Diabetes Study Group UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex Diabetes Care 20 1997 1683 1687
9. E.S. Ford The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study Atherosclerosis 173 2004 307
10. R.S. Elkeles, J.R. Diamond, and C. Poulter Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study Diabetes Care 21 1998 641 648
11. Diabetes Atherosclerosis Intervention Study Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 2001 905 910
12. H.B. Rubins, S.J. Robins, and D. Collins Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) Arch Intern Med 162 2002 2597 2604
13. FIELD Study Investigators The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [ISRCTN64783481] Cardiovasc Diabetol 3 2004 9
14. E. Lee Statistical methods for survival data analysis 2nd ed. 1992 Wiley New York
15. D. Cox Regression methods of life tables (with discussion) J R Stat Soc B 34 1972 187 220
16. T. Therneau, and P. Grambsch Modelling survival data: extending the Cox model 2000 Springer New York
17. P.M. Rothwell Subgroup analysis in randomised controlled trials: importance, indications, and interpretation Lancet 365 2005 176 186
18. K. Schulz, and D. Grimes Multiplicity in randomised trials II: subgroup and interim analyses Lancet 365 2005 1657 1661
19. J. Simes, M. Voysey, and R. O'Connell A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials PLoS One 5 2010 e8580
20. P. Koskinen, M. Manttari, and V. Manninen Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study Diabetes Care 15 1992 820 825
21. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
22. M. Jun, C. Foote, and J. Lv Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
23. M.I. Harris Undiagnosed NIDDM: clinical and public health issues Diabetes Care 16 1993 642 652
24. M.J. Chapman Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives Atherosclerosis 171 2003 1 13
25. Cholesterol Treatment Trialists Collaborators Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
26. F.M. Sacks, and H. Campos Dietary therapy in hypertension N Engl J Med 362 2010 2102 2112
27. A.C. Keech, P. Mitchell, and P.A. Summanen Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697
28. K. Rajamani, P.G. Colman, and L.P. Li Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial Lancet 373 2009 1780 1788
29. T.M. Davis, R. Ting, and J.D. Best Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2011 280 290